The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy.
Damiano PaolicelliSergio IannazzoLaura SantoniAntonio IaffaldanoValentina Di LecceAlessia ManniVito LavolpeCarla TortorellaMariangela D'OnghiaVita DirenzoElisa PumaMaria TrojanoPublished in: PloS one (2016)
The results of this economic evaluation suggest the presence of an association between NAb+ status and increased costs for the management of RRMS in Italy. Further pharmacoeconomic research will be needed to confirm this first result.